Consumer comments close Wednesday, 16 September 2026. The Pharmaceutical Benefits Advisory Committee (PBAC) will consider an application to list sepiapterin (Sephience®) on the Pharmaceutical Benefits Scheme (PBS) at its November 2026 meeting. Sepiapterin, used in...
From 1 August 2026, nitisinone (Orfadin®) will become available through the Pharmaceutical Benefits Scheme (PBS) for the treatment of hereditary tyrosinaemia type 1 (HT1) under certain conditions. New patients commencing treatment with Orfadin® from 1 August will...
You’re invited to the Metabolic Dietary Disorders Association Annual General Meeting Date: 23 November 2025 Time: 10.30am – 11am Place: Fairmont Resort, 1 Sublime Point Road, Leura NSW 2780 Members and Invited Guests Welcome! Hear about our activities over...
MDDA met with the IEM Department today and they have requested MDDA share the following statement:” “There has been a delay to the monthly payment of the Inborn Errors of Metabolism (IEM) program in August 2022 due to administrative issues within the Department...
The Metabolic Dietary Disorders Association is extremely pleased with the decision of the Pharmaceutical Benefits Advisory Committee (PBAC) to recommend the listing of Kuvan (sapropterin dihydrochloride) on the Pharmaceutical Benefits Scheme (PBS) for maternal women...
